WhiteOak Capital Pharma and Healthcare Fund Regular Growth

Fund Overview

Fund Size

₹409 Cr

Expense Ratio

2.38%

ISIN

INF03VN01878

Minimum SIP

₹500

Exit Load

1.00%

Inception Date

06 Feb 2024

About this fund

This fund has been in existence for 1 years, 6 months and 18 days, having been launched on 06-Feb-24.
As of 22-Aug-25, it has a Net Asset Value (NAV) of ₹14.13, Assets Under Management (AUM) of 409.43 Crores, and an expense ratio of 2.38%.

WhiteOak Capital Pharma and Healthcare Fund Regular Growth has given a CAGR return of 25.12% since inception.
The fund's asset allocation comprises around 91.74% in equities, 0.00% in debts, and 8.26% in cash & cash equivalents.
You can start investing in WhiteOak Capital Pharma and Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+15.65%

+4.67% (Cat Avg.)

Since Inception

+25.12%

— (Cat Avg.)

Portfolio Summaryas of 31st July 2025

Equity	₹375.59 Cr	91.74%
Others	₹33.83 Cr	8.26%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹31.54 Cr	7.70%
Sun Pharmaceuticals Industries Ltd	Equity	₹27.18 Cr	6.64%
Fortis Healthcare Ltd	Equity	₹21.83 Cr	5.33%
Cipla Ltd	Equity	₹19.58 Cr	4.78%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹18.78 Cr	4.59%
Laurus Labs Ltd	Equity	₹18.18 Cr	4.44%
Divi's Laboratories Ltd	Equity	₹17.36 Cr	4.24%
Krishna Institute of Medical Sciences Ltd	Equity	₹15.9 Cr	3.88%
Anthem Biosciences Ltd	Equity	₹13.32 Cr	3.25%
Net Receivables / (Payables)	Cash - Collateral	₹12.03 Cr	2.94%
Apollo Hospitals Enterprise Ltd	Equity	₹11.99 Cr	2.93%
Abbott India Ltd	Equity	₹10.65 Cr	2.60%
Glenmark Pharmaceuticals Ltd	Equity	₹10.19 Cr	2.49%
Thyrocare Technologies Ltd	Equity	₹9.71 Cr	2.37%
Torrent Pharmaceuticals Ltd	Equity	₹9.15 Cr	2.23%
Gland Pharma Ltd	Equity	₹8.9 Cr	2.17%
Vijaya Diagnostic Centre Ltd	Equity	₹8.49 Cr	2.07%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹7.8 Cr	1.90%
Clearing Corporation Of India Ltd	Cash - Repurchase Agreement	₹7.5 Cr	1.83%
Kovai Medical Center & Hospital Ltd	Equity	₹7.43 Cr	1.82%
Emcure Pharmaceuticals Ltd	Equity	₹7.07 Cr	1.73%
Sai Life Sciences Ltd	Equity	₹6.97 Cr	1.70%
Eris Lifesciences Ltd Registered Shs	Equity	₹6.87 Cr	1.68%
Ajanta Pharma Ltd	Equity	₹6.57 Cr	1.60%
Neuland Laboratories Ltd	Equity	₹6.01 Cr	1.47%
Jupiter Life Line Hospitals Ltd	Equity	₹5.86 Cr	1.43%
Pfizer Ltd	Equity	₹5.49 Cr	1.34%
AstraZeneca Pharma India Ltd	Equity	₹5.24 Cr	1.28%
Treasury Bills	Bond - Gov't/Treasury	₹4.96 Cr	1.21%
Lupin Ltd	Equity	₹4.72 Cr	1.15%
Alembic Pharmaceuticals Ltd	Equity	₹4.48 Cr	1.10%
Navin Fluorine International Ltd	Equity	₹4.44 Cr	1.09%
Acutaas Chemicals Ltd	Equity	₹4.18 Cr	1.02%
Piramal Pharma Ltd	Equity	₹4.18 Cr	1.02%
FDC Ltd	Equity	₹3.73 Cr	0.91%
Shilpa Medicare Ltd	Equity	₹3.67 Cr	0.90%
Rainbow Childrens Medicare Ltd	Equity	₹3.28 Cr	0.80%
India (Republic of)	Bond - Short-term Government Bills	₹3.1 Cr	0.76%
Strides Pharma Science Ltd	Equity	₹2.77 Cr	0.68%
Supriya Lifescience Ltd	Equity	₹2.72 Cr	0.67%
Shaily Engineering Plastics Ltd	Equity	₹2.57 Cr	0.63%
Dr Agarwal'S Eye Hospital Ltd	Equity	₹2.56 Cr	0.63%
PB Fintech Ltd	Equity	₹2.38 Cr	0.58%
Jubilant Ingrevia Ltd Ordinary Shares	Equity	₹2.02 Cr	0.49%
OneSource Specialty Pharma Ltd	Equity	₹2 Cr	0.49%
182 Days Tbill	Bond - Gov't/Treasury	₹1.99 Cr	0.49%
364 DTB 03102025	Bond - Gov't/Treasury	₹1.98 Cr	0.48%
Laxmi Dental Ltd	Equity	₹1.75 Cr	0.43%
Zota Health Care Ltd	Equity	₹1.75 Cr	0.43%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹1.61 Cr	0.39%
Mankind Pharma Ltd	Equity	₹1.37 Cr	0.34%
Poly Medicure Ltd	Equity	₹1.34 Cr	0.33%
364 DTB 28082025	Bond - Gov't/Treasury	₹0.5 Cr	0.12%
91 Days Tbill (Md 28/08/2025)	Bond - Gov't/Treasury	₹0.5 Cr	0.12%
91 Days Tbill Red 16-10-2025	Bond - Gov't/Treasury	₹0.49 Cr	0.12%
India (Republic of)	Bond - Short-term Government Bills	₹0.4 Cr	0.10%
182 Days Tbill	Bond - Gov't/Treasury	₹0.2 Cr	0.05%
91 Days Tbill Red 23-10-2025	Bond - Gov't/Treasury	₹0.2 Cr	0.05%

Allocation By Market Cap (Equity)

Allocation By Credit Quality (Debt)

AAA

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹359.99 Cr	87.93%
Basic Materials	₹13.22 Cr	3.23%
Financial Services	₹2.38 Cr	0.58%

Risk & Performance Ratios

Fund Managers

Piyush Baranwal

Since February 2024

Ramesh Mantri

Since February 2024

Trupti Agrawal

Since May 2025

Dheeresh Pathak

Since February 2024

Ashish Agrawal

Since January 2025

Additional Scheme Detailsas of 31st July 2025

ISIN

INF03VN01878

Expense Ratio

2.38%

Exit Load

1.00%

Fund Size

₹409 Cr

Age

1 year 6 months

Lumpsum Minimum

₹500

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.4%	1.0%	₹670.42 Cr	-
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.3%	1.0%	₹670.42 Cr	-
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹341.35 Cr	-
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹341.35 Cr	-
PGIM India Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹112.33 Cr	-
PGIM India Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹112.33 Cr	-
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹409.43 Cr	15.7%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹409.43 Cr	17.7%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹10.65 Cr	4.8%
Kotak Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹485.27 Cr	5.9%
Kotak Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹485.27 Cr	4.2%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹1936.05 Cr	13.5%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹1936.05 Cr	14.9%
Nippon India Pharma Fund Direct Growth Very High Risk	0.9%	1.0%	₹8736.57 Cr	3.8%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.9%	1.0%	₹6103.96 Cr	8.7%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	1.0%	1.0%	₹6103.96 Cr	9.6%
DSP Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹3190.15 Cr	4.9%
DSP Healthcare Fund Regular Growth Very High Risk	1.9%	0.0%	₹3190.15 Cr	3.5%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.2%	1.0%	₹90.98 Cr	6.6%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.5%	1.0%	₹90.98 Cr	5.3%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹409.22 Cr	-9.3%
quant Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹409.22 Cr	-10.8%
UTI Healthcare Fund Direct Growth Very High Risk	1.3%	1.0%	₹1146.13 Cr	9.4%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹4026.55 Cr	11.6%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹1339.00 Cr	3.6%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹1339.00 Cr	5.1%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹146.40 Cr	4.8%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹4026.55 Cr	10.4%
Nippon India Pharma Fund Regular Growth Very High Risk	1.8%	1.0%	₹8736.57 Cr	2.9%
UTI Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹1146.13 Cr	8.4%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹20.49 Cr	4.6%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹942.04 Cr	-0.8%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2908.21 Cr	3.1%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2908.21 Cr	4.6%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹235.68 Cr	1.3%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	0.0%	₹235.68 Cr	3.2%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹36.57 Cr	4.7%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹871.69 Cr	1.6%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.0%	1.0%	₹871.69 Cr	2.9%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹21.23 Cr	6.8%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Regular Growth?

The NAV of WhiteOak Capital Pharma and Healthcare Fund Regular Growth, as of 22-Aug-2025, is ₹14.13.

What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Regular Growth?

The fund's allocation of assets is distributed as 91.74% in equities, 0.00% in bonds, and 8.26% in cash and cash equivalents.

Who manages the WhiteOak Capital Pharma and Healthcare Fund Regular Growth?

The fund managers responsible for WhiteOak Capital Pharma and Healthcare Fund Regular Growth are:-

Piyush Baranwal
Ramesh Mantri
Trupti Agrawal
Dheeresh Pathak
Ashish Agrawal

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Fund Overview

Fund Size

₹409 Cr

Expense Ratio

2.38%

ISIN

INF03VN01878

Minimum SIP

₹500

Exit Load

1.00%

Inception Date

06 Feb 2024

Risk Level

Your principal amount will be at Very High Risk